We use our proprietary Synthetic Replicon for Gene delivery (SynRGY) technology to deliver the genetic code of a virally-derived RNA molecule. Once the RNA molecule enters a cell, it self-replicates to create thousands of copies itself and uses the cell’s own machinery to create abundant amounts of proteins responsible for drug resistance. This process mimics a viral infection and educates the immune system to recognize tumor cells that express these proteins responsible for drug resistance. This also generates immune memory that is deployed throughout the body, so drug resistant cells are removed from tumors as they arise. This technology can be delivered using a simple needle and syringe administered in the muscle.
This technology is also advantaged from a manufacturing perspective. Because this technology uses the body’s own cells a protein factory, only small doses are required. Because of these doses, this technology requires a small manufacturing footprint. In fact, a 1 liter bioreactor may be capable of producing 5 million doses. These small doses lead to lower cost of goods and a lower probability of encountering any unwanted side effects.
Our team has extensive drug development expertise with this modality. We have previously developed synthetic, RNA-based platforms and CMC frameworks for major pharmaceutical and biotechnology organizations.